• Explore /
  • Poster
  • / Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.

Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.

Abstract Poster

Authors

null

Aristotelis Bamias

HECOG, University of Athens, Medical School, Athens, Greece

Aristotelis Bamias , Meletios A. Dimopoulos , Flora Zagouri , Anne-Sophie Veillard , Jens Kosse , Ana Santaballa , Mansoor Raza Mirza , Gianna Tabaro , Ignace Vergote , Haiko Bloemendal , Maria Lykka , Anne Floquet , Chee Lee , Val Gebski , Eric Pujade-Lauraine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT00976911

Citation

J Clin Oncol 33, 2015 (suppl; abstr 5551)

DOI

10.1200/jco.2015.33.15_suppl.5551

Abstract #

5551

Poster Bd #

109

Abstract Disclosures

Similar Posters

First Author: Chee Lee

First Author: Martin R. Stockler

First Author: Gordon Taylor Moffat

First Author: Felicia Roncolato